Class summary at a glance.

Every drug in the Recombinant Human Growth Hormone class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $261.4Mcombined across class
Total Rx claims: 44K8K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Somatropin

Brand: GENOTROPIN · 44K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 1995-12-20

Brand-only (no generics) 2604 plans require PA Discontinued

Low NADAC$30.90

→

Avg plan cost$739.98

Part D spend $261.2M 24× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Lonapegsomatropin-Tcgd

Brand: Skytrofa · 33 Part D claims (CY24) · First FDA approval: 2021-08-25

Brand-only (no generics) 168 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $262394

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.